These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 18673198)

  • 1. Lysosomal storage diseases and the blood-brain barrier.
    Begley DJ; Pontikis CC; Scarpa M
    Curr Pharm Des; 2008; 14(16):1566-80. PubMed ID: 18673198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier.
    Urayama A; Grubb JH; Sly WS; Banks WA
    Proc Natl Acad Sci U S A; 2004 Aug; 101(34):12658-63. PubMed ID: 15314220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuronopathic lysosomal storage disorders: Approaches to treat the central nervous system.
    Scarpa M; Bellettato CM; Lampe C; Begley DJ
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):159-71. PubMed ID: 25987170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epinephrine enhances lysosomal enzyme delivery across the blood brain barrier by up-regulation of the mannose 6-phosphate receptor.
    Urayama A; Grubb JH; Banks WA; Sly WS
    Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12873-8. PubMed ID: 17646643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice.
    Blanz J; Stroobants S; Lüllmann-Rauch R; Morelle W; Lüdemann M; D'Hooge R; Reuterwall H; Michalski JC; Fogh J; Andersson C; Saftig P
    Hum Mol Genet; 2008 Nov; 17(22):3437-45. PubMed ID: 18713755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic manipulation of lysosomal enzyme transport across the blood-brain barrier.
    Urayama A; Grubb JH; Sly WS; Banks WA
    J Cereb Blood Flow Metab; 2016 Mar; 36(3):476-86. PubMed ID: 26661222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mannose 6-phosphate receptor-mediated transport of sulfamidase across the blood-brain barrier in the newborn mouse.
    Urayama A; Grubb JH; Sly WS; Banks WA
    Mol Ther; 2008 Jul; 16(7):1261-6. PubMed ID: 18443601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The blood-brain barrier and neurodegenerative lysosomal storage diseases].
    Urayama A
    Brain Nerve; 2013 Feb; 65(2):153-63. PubMed ID: 23399673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New strategies for enzyme replacement therapy for lysosomal storage diseases.
    Grubb JH; Vogler C; Sly WS
    Rejuvenation Res; 2010; 13(2-3):229-36. PubMed ID: 20345279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases.
    Jakóbkiewicz-Banecka J; Wegrzyn A; Wegrzyn G
    J Appl Genet; 2007; 48(4):383-8. PubMed ID: 17998597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins.
    Pardridge WM
    Adv Drug Deliv Rev; 2022 May; 184():114234. PubMed ID: 35307484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant caprine 3H-[N-acetylglucosamine-6-sulfatase] and human 3H-[N-acetylgalactosamine-4-sulfatase]: plasma clearance, tissue distribution, and cellular uptake in the rat.
    Jones MZ; Brumfield LK; King BM; Hopwood JJ; Byers S
    J Mol Neurosci; 1998 Dec; 11(3):223-32. PubMed ID: 10344792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glyco-engineering strategies for the development of therapeutic enzymes with improved efficacy for the treatment of lysosomal storage diseases.
    Oh DB
    BMB Rep; 2015 Aug; 48(8):438-44. PubMed ID: 25999178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysosomal enzymes may cross the blood-brain-barrier by pinocytosis: implications for enzyme replacement therapy.
    Baldo G; Giugliani R; Matte U
    Med Hypotheses; 2014 Apr; 82(4):478-80. PubMed ID: 24560457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy.
    Beck M
    Hum Genet; 2007 Mar; 121(1):1-22. PubMed ID: 17089160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
    Thomas R; Kermode AR
    Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy for lysosomal storage diseases.
    Lachmann RH
    Curr Opin Pediatr; 2011 Dec; 23(6):588-93. PubMed ID: 21946346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.
    Solomon M; Muro S
    Adv Drug Deliv Rev; 2017 Sep; 118():109-134. PubMed ID: 28502768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The final frontier -- crossing the blood-brain barrier.
    Sly WS; Vogler C
    EMBO Mol Med; 2013 May; 5(5):655-7. PubMed ID: 23653302
    [No Abstract]   [Full Text] [Related]  

  • 20. miR-143 Regulates Lysosomal Enzyme Transport across the Blood-Brain Barrier and Transforms CNS Treatment for Mucopolysaccharidosis Type I.
    Lin Y; Wang X; Rose KP; Dai M; Han J; Xin M; Pan D
    Mol Ther; 2020 Oct; 28(10):2161-2176. PubMed ID: 32610100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.